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Cystic ﬁbrosis (CF) diagnostic microbiology has evolved from a focus on Staphylococcus aureus as primary pathogen to identiﬁcation of the
contribution of Pseudomonas aeruginosa and other non-fermenting gram negatives; studies of the lung microbiome have added new
complexity. This review summarizes state-of-the art culture methods and makes recommendations for addition of non-culture based methods in
the diagnostic laboratory. Plating on selective media is recommended, with organism identiﬁcation by matrix assisted laser desorption-time of
ﬂight mass spectroscopy and real-time polymerase chain reaction (PCR) supplanting both biochemical identiﬁcation and other less accurate and
more time-consuming molecular methods. Conventional antibiotic susceptibility testing, possibly at less frequent intervals, remains the standard
but more CF-relevant methods may arise in the future. There is a role for direct identiﬁcation of organisms in clinical samples using quantitative
real-time PCR, next generation sequencing, and metagenomic studies for the re-examination of samples that do not yield traditional CF
pathogens.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Microbiology; Bacteria; Susceptibility testing
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Cystic fibrosis (CF) is characterized by chronic airway
infections with intermittent pulmonary exacerbations. The
microbiology of CF airway infections has for many decades
been determined by bacterial and fungal culture methods,
focusing on the most commonly isolated organisms includ-
ing Staphylococcus aureus, Pseudomonas aeruginosa, and
Haemophilus influenzae [1]. However, many other opportu-
nistic organisms not commonly recovered from healthy individ-
uals have been associated with evolution of the airway disease in
CF individuals over the last decade including gram negative
non-lactose fermenting bacilli such as Burkholderia cepacia
complex, Stenotrophomonas maltophilia, Achromobacter spp.,
and Inquilinus limosus; non-tuberculous mycobacteria; and
fungal organisms, both yeasts and molds [1–3]. In addition,
respiratory viruses have been examined, although a specific role
for viruses in CF pulmonary disease has not been clearly defined.
More recently, non-culture based methods have added to our
understanding of the polymicrobial nature of CF airway
infections. Many organisms not previously recovered from the
CF airway have been reported from patient samples using
polymerase chain reaction (PCR) and deep sequencing [2,4–6].
These include viridans streptococcus, Prevotella spp., Veillonella
spp. and other anaerobic organisms, none of which would have
been detected using currently recommended diagnostic culture
methods for CF respiratory samples. The role of anaerobes and
microaerophilic organisms in the progression of CF airway
disease is not clear. While Streptococcus milleri has been reported
to be a clinically relevant pathogen in CF because of its association
with pulmonary exacerbations [7], studies by Zemanick and
others have reported that anaerobes identified from sputum by
sequencing are associated with less inflammation and higher lung
function than P. aeruginosa [7,8].
Studies of the CF lung microbiome will not be covered in this
review and non-culture based methods for direct examination of
CF airway samples by PCR and next generation sequencing will
only be reviewed briefly, because these strategies are not yet
recommended for routine use in CF clinical diagnostic laborato-
ries. However, non-culture based methods that are available in
clinical laboratories including mass spectroscopy, PCR, and 16S
rRNA sequencing for identification of isolated organisms will be
addressed.
Although studies of the lung microbiome offer insight into
the polymicrobial nature of CF airway infections, they also
add a significant degree of complexity to an already
multifaceted biological system. There are many unanswered
questions: 1)Which organisms or combinations of pathogens and
colonizing organisms are pathogenic in CF? 2) Are availableculture methods adequate for the isolation and identification of
these organisms? 3) How best can we characterize the interaction
between different species? 4) What is the biological impact of
antimicrobial therapy on CF airway infections? 5) What is the
best method to determine antimicrobial susceptibility in vitro?
The overall goal of this manuscript is to summarize the
current status of culture-based methods for CF samples and to
make recommendations for the use of specific non-culture
based methods in conjunction with CF-specific specimen
processing and culture in order to more clearly understand CF
airway infections.
2. Bacterial cultures of CF respiratory samples
2.1. Optimum respiratory sample for CF airway infection
A recent study has demonstrated that the site of sampling is
critical for an accurate overview of the bacterial population.
Identification of different organisms based on 16S amplicon
pyrosequencing analysis was reported comparing direct lung
samples obtained at the time of transplantation with oropharyn-
geal swabs and expectorated sputum samples. Oropharyngeal
swabs in particular poorly reflected the lung microbiota [9].
Selection of the optimum sample for culture is a balance between
accuracy and convenience; patient safety and preference must
also be considered. Possible samples for culture-based microbi-
ological diagnosis in CF airway infections include bronchoalve-
olar lavage fluid, expectorated or hypertonic saline-induced
sputum, cough swabs and oropharyngeal swabs. Each has
advantages and disadvantages. The deepest possible sample and
presumably the most accurate is from a bronchoalveolar lavage.
However, obtaining this sample is invasive, particularly in
children for whom general anesthesia is usually required, and
has a low but quantifiable risk of contamination by oral flora.
Traditionally, sputum samples have been used as a surrogate
for lower airway cultures. Expectoration of sputum for culture
is far less invasive than bronchoalveolar lavage; however, not
all individuals with CF are expectorators. Although induction
of sputum can be useful in non-expectorating patients, this
technique is not routinely performed at all CF centers and
requires clinical expertise and patient proficiency. In addition,
some patients experience bronchospasm with the use of
hypertonic saline during sputum induction. When obtaining
either expectorated or induced sputum, there is a higher
likelihood of oral contamination than with bronchoalveolar
lavage. More superficial samples include swabs of the
oropharynx and cough swabs. While convenient and non-
invasive, oropharyngeal and cough swabs are more likely to
contain oral flora and are far less sensitive for S. aureus and P.
Table 1
Current recommendations for the use of selectivemedia in CF clinical microbiology.
Organism Recommended media
Pseudomonas aeruginosa None
Burkholderia cepacia complex BCSA
MAST selective agar
Staphylococcus aureus CHROMagar Staph aureus selective and
differential agar
Mannitol salt agar
Haemophilus influenzae Blood agar supplemented with hemin, plus
bacitracin a
Chocolate agar, plus cefsulodin
a Anaerobic incubation is also recommended with this medium.
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(sputum or bronchoalveolar lavage fluid). The negative
predictive value for P. aeruginosa is high in young children,
but declines with age [10]. In addition, swabs are considered
inadequate for the culture of mycobacteria. Overall, the most
commonly cultured CF respiratory sample is expectorated
sputum.
2.2. Role of the gram stain and other observational methods for
evaluation of CF respiratory samples
Gram staining is a procedure that is generally recommended
for processing all sputum samples. However, its utility in CF
microbiology has been questioned. Nair et al. [11] found that
the use of standard gram staining criteria would have resulted in
rejection of 41% of samples, the majority of which were both
purulent, based on examination of the sample, and culture
positive for gram positive and gram negative CF pathogens. In
that study each sample was visually inspected and areas of
purulence were selected for culture. Results suggested that
routine gram staining is not necessary for evaluating the quality
or results of CF sputum samples.
Another technique that has been suggested for the evaluation
of sputum quality is the use of a colorimetric card (BronkoTest®;
Williams Medical), which is a visual method to assess sputum
color. The BronkoTest® has been validated for use for the
management of chronic obstructive pulmonary disease and a
recent study from Elborn et al. used it for a study of biomarkers in
CF [12].
2.3. Use of selective media and dilutional methods for bacterial
and fungal cultures of CF samples
CF airway infections are polymicrobial and contain both
relatively rapidly growing organisms and those that are auxo-
trophic and/or slow growing, making it possible for some
organisms such as a mucoid P. aeruginosa to overgrow or
obscure slower growing organisms or those present in lesser
numbers. In addition, CF sputum samples are often viscous and
non-homogenous with areas of purulence and mucus plugs that
might trap organisms. Thus, special processing is recommended
to improve the accuracy of CF culture results. Selective medium
that inhibits the overgrowth of non-target organisms can be very
helpful in the recovery of fastidious organisms and the use of
solubilizing agents such as dithiothreitol with subsequent
specimen dilution can improve detection of organisms present at
a lower density.
Selective medium specific for P. aeruginosa is not recom-
mended; it is unnecessary and may actually inhibit organism
growth [13]. However, the use of a selective medium is strongly
recommended for B. cepacia complex, because the organism has a
high clinical impact, a high risk of transmissibility, and a relatively
slow growth [13,14] (Table 1). Numerous media have been
developed for this purpose including OFPBL, PC agar, MAST
selective agar and BCSA. The latter two have the highest
sensitivity and specificity for recovery and are recommended. It
is also advised that these plates be incubated at 37 °C for aprolonged period and subsequently held at room temperature to
complete a week of incubation. Although BCSA is highly selective
for B. cepacia complex, other colistin-resistant organisms
including Achromobacter spp., S. maltophilia or I. limosus would
not be detected [15]. With the emergence of colistin-resistant
bacteria among CF patients, the use of a less selectivemediumwith
rapid identification using matrix assisted laser desorption-time of
flight mass spectrometry (MALDI-TOF MS) may actually be
beneficial in laboratories with the ability to perform MALDI-TOF
MS identification (see Organism identification by MALDI-TOF
MS).
Selective media for H. influenzae and S. aureus can be very
helpful in recovery of these organisms from CF samples [13].
H. influenzae, in particular, is fastidious and easily overgrown
by P. aeruginosa. Recommended media include blood agar
supplemented with hemin, containing bacitracin and incubated
anaerobically, or chocolate agar containing cefsulodin (Table 1).
The use of a selective medium such as mannitol salt agar or
CHROMagar Staph aureus selective and differential agar signif-
icantly increases the yield of S. aureus from CF samples compared
with non-selective medium (Table 1). Although Staphylococcal
selective media are somewhat more expensive to use, the cost is
offset by a decrease in laboratory technologist time for subcultures
and confirmatory testing, because the chromogenic markers in the
media help distinguish S. aureus from coagulase negative
staphylococcus. Another selective medium that has been proposed
for CF samples is McKay agar for the routine quantification of the
S. milleri group [7].
A recent study of the CF airway microbiome enriched by
culture-dependent techniques suggests that additional media,
anaerobic cultivation and extended incubation times may help
in the recovery of previously overlooked species [4]. However,
until the clinical relevance of these species has been clarified,
we do not recommend the routine use of additional culture
conditions for CF clinical samples.
Increasing attention is being paid to the role of fungal species
in older children and adults with CF. However, at this time the
clinical relevance of these fungi in CF has not been fully
delineated. Aspergillus fumigatus has been associated with
allergic bronchopulmonary aspergillosis in CF, but invasive
disease is rarely seen and the use of antifungal therapy remains
uncommon. Other filamentous fungi, including members of the
Pseudallescheria/Scedosporium group, are of concern and may
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prevalence of fungal pathogens in CF samples vary among
different geographical areas; this may be related to a lack of
standardization in the methods used to evaluate CF sputum
samples for filamentous fungi [16]. Sabouraud dextrose
medium with or without selective antibiotics is useful in the
recovery of fungi from CF samples and may be enhanced by
prolonged incubation [13]. Solubilization of CF samples using
dithiothreitol reduces disulfide bonds and is helpful for
disruption of mucus plugs and homogenization of sputum. In
some laboratories, samples are subsequently serially diluted
prior to plating on selective media to facilitate detection of
organisms present at a low density. Although the density of
organisms in respiratory samples is frequently reported
semi-quantitatively (by arbitrary scores e.g. 1+, 2+, 3+, 4+),
actual quantitation of bacterial density in CF sputum has been
used as a microbiological endpoint in clinical trials testing the
efficacy of new antimicrobial therapies [17,18]. Quantitative
cultures are also used clinically in a number of laboratories that
process CF samples (personal communication, J. Burns;
personal communication F. Accurso), but the clinical utility
of this method is controversial.2.4. Mycobacterial culture methods
As the clinical and epidemiologic importance of nontuberculous
mycobacteria especially members of theMycobacterium abscessus
complex is increasingly recognized in CF, the CF Foundation has
recommended that mycobacterial cultures be performed annually
especially in individuals receiving chronic azithromycin therapy.
Acid fast staining of sputum smears using a fluorochrome method
such as auramine–rhodamine is recommended in preference to the
Ziehl-Neelsen and Kinyoun stains as the latter are reported to be
less sensitive for non-tuberculous mycobacteria [13]. Sputum
smears can be very useful in evaluating the burden of organisms in
the lung and the results may impact treatment decisions.
To enhance isolation of mycobacteria from CF samples,
decontamination with N-acetyl-L-cysteine, sodium hydroxide
and oxalic acid [19] is recommended to minimize the
overgrowth of P. aeruginosa and other rapid-growing,
non-fastidious gram negative organisms. Bacterial density
may decrease with these decontamination procedures, so only
sputum (expectorated or induced) and bronchoalveolar lavage
fluid are considered adequate samples for mycobacterial
culture. CF samples should both be inoculated into a liquid
medium and plated onto a solid medium such as the
Middlebrook or Lowenstein–Jensen medium. Further recom-
mendations will be forthcoming from the CF Foundation/
European CF Society consensus committee on non-tuberculous
mycobacteria, expected to be completed later this year (personal
communication, C. Haworth). Culture on sheep blood agar
medium following decontamination may also be a useful
methodology (personal communication, J-MRolain). In addition,
culture on BCSA with extended incubation (5 to 14 days) may
improve the recovery rate of rapidly growing mycobacteria in CF
sputum samples [20].3. Organism identification
3.1. Biochemical identification of gram negative organisms
Once organisms are isolated in pure culture, some may
readily be identified by appearance (colonial morphology,
pigment production, beta-hemolysis on sheep's blood agar,
growth temperature) combined with a few simple assays
(oxidase, catalase). However, because of the many phenotypic
changes that may be induced in the CF airway related to
selective pressure and hypermutability, gram negative CF
isolates often require additional testing [1]. These traditional
identification methods use a much larger panel of biochemical
and chromogenic assays and may take up to 72 h after pure
growth on a subculture plate to confirm an identification.
Multiple studies have identified the poor performance of
commercially available biochemical identification systems for the
identification of gram negative CF pathogens [2,3]. Difficulties
with these systems arise for several reasons including relatively
slow organism growth rates, phenotypic variability among CF
isolates, and inadequate system databases.3.2. Organism identification by polymerase chain reaction (PCR)
The clinical importance and infection control implications of
specific bacterial organisms such as P. aeruginosa, B. cepacia
complex and M. abscessus complex in CF make rapid and
accurate identification imperative. The use of 16S rRNA PCR
amplification and sequencing, and real-time PCR amplification
of multiple gene targets can significantly improve the accuracy
of identification. The former is considered a reference standard
for organism identification. However, because of the (at times)
limited interspecies discriminatory ability of 16S rRNA
sequencing, the amplification of multiple gene targets may be
necessary and can be substituted for the less rapid and more
expensive 16S sequencing method. Many clinical laboratories
perform real time PCR identification on a daily basis and in a
significant number it has supplanted all but the most basic
biochemical testing.
Multiple potential gene targets have been recognized for
PCR identification of P. aeruginosa, B. cepacia complex,
S. maltophilia, and Achromobacter spp. [2,21]. However,
in order to accurately discriminate between B. cepacia complex,
Pandoraea spp., Achromobacter spp. and some non-aeruginosa
Pseudomonas spp. single or multiple gene sequencing is often
necessary [22].
Accurate identification of non-tuberculous mycobacteria is
important to distinguish organisms with potential for increased
transmissibility and virulence and decreased antimicrobial sus-
ceptibility. Molecular methods hold the most promise for accurate
identification.Mycobacterium avium complex includesM. avium,
Mycobacterium intracellulare and several other related identified
and unidentified species. Similarly, M. abscessus has been
recognized as a complex including two subspecies, M. abscessus
subsp. bolletii and M. abscessus subsp. abscessus [23]. Again,
multiple gene sequencing is necessary [24].
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MALDI-TOF MS is a more recent and rapid method for
bacterial identification and is being used routinely in many clinical
microbiology laboratories. The rapidity of this method for bacterial
identification has been a revolution in clinical microbiology
laboratories because it is now possible to identify the majority of
the colonies growing on agar plates [21]. It is an accurate and very
rapid technique for identification of many organisms and has been
evaluated for identification of CF pathogens [25]. MALDI-TOF
MS relies on generation of a unique peptidic spectrum for each
isolate which can then be compared with a database for organism
identification. A recent study by Desai et al. demonstrated that the
use of a bacterial database that was not supplemented with
CF-specific reference strains yielded complete genus and species
agreement in 92% of isolates from 24 CF samples, with genus
agreement in 98% [25]. Organisms only identifiable to the genus
level included Achromobacter xylosoxidans, Acinetobacter spp.,
andRalstonia pickettii; the onlymember of theB. cepacia complex
that can be reliably identified (greater than 95%) by MALDI-TOF
MS is Burkholderia multivorans. Thus, identification of B. cepacia
complex organisms byMALDI-TOFMS is not recommended. As
noted above in the section on PCR identification, these species and
others including non-aeruginosa Pseudomonas often require
sequence-based methods of identification.
MALDI-TOF MS can be used for the rapid identification of
other organisms, as well. Del Chierico et al. have reported its use
for the identification of filamentous fungi from CF patients with
good accuracy [26]. The use of MALDI-TOF MS for identifica-
tion of mycobacteria is also being explored. For mycobacterial
identification, Saleeb et al. have reported an optimized protein
extraction protocol and created a mycobacterial database that
permits identification of most strains of mycobacteria isolated
from solid growth media [27]. While not yet in routine use, this
technique offers the possibility of accurate and more rapid
identification of these emerging CF pathogens. Finally, because
an exhaustive analysis can be done with MALDI-TOF MS,
identification of putative new and/or emerging bacteria is now
possible in the context of CF. For example this technique allowed
identification of a cluster of CF patients colonized with
Corynebacterium pseudodiphtheriticum, an emerging respiratory
pathogen that had not previously been reported in CF patients
[28].
3.4. Detection and identification of small colony variant S. aureus
Genetic variants of S. aureus called small colony variants
(SCVs) emerge during chronic CF infections and are associated
with poor clinical outcomes in a pediatric population [29]. SCVs
grow slowly on many culture media because they have metabolic
defects, so they may be very difficult to identify in polymicrobial
CF respiratory cultures; use of a Staphylococcal selective agar is
necessary to avoid overgrowth of other organisms and prolonged
incubation is critical to detect growth. To detect S. aureus SCVs,
it is useful to subculture each S. aureusmorphotype from primary
isolation medium onto both a supplemented medium that will
readily support normal colony growth and a medium on whichsmall colony growth is demonstrated. A simple method using
media routinely available in all clinical laboratories that meets
these requirements was recently published by Wolter et al. [29].
All S. aureus isolates were subcultured onto blood agar from
primary isolation plates with incubation in ambient air at 35 °C
for 24–48 h; fastidious small colonies were subcultured to blood,
chocolate and brucella agars, again with incubation in ambient air
at 35 °C for 24–48 h. SCVs were identified by slow growth on
the blood agar plate compared with robust growth on the brucella
and chocolate agars. They were typically non-hemolytic and
lacked pigmentation when grown on blood agar.
An important finding in that study was that only 53 of the 81
cultures positive for S. aureus SCVs had wild-type S. aureus
isolated from the same culture [29]. If the SCVs had not been
detected using enhanced culture techniques, 1/3 of S. aureus
positive cultures might have been missed (personal communica-
tion, L. Hoffman). With increasing recognition of the clinical
significance of S. aureus SCVs, adoption of a clinical laboratory
protocol for their detection becomes increasingly relevant.
4. Antibiotic susceptibility testing
4.1. Standard susceptibility testing
For a number of years, the accuracy of antibiotic susceptibility
testing for CF isolates ofP. aeruginosawas questioned, primarily
because of concerns regarding slow growth, auxotrophy and the
impact of mucoid exopolysaccharide. Subsequent testing dem-
onstrated that the agar diffusion methods including disk diffusion
susceptibility testing and the agar-based stable gradient methods
(Etest®) compared favorably with reference broth microdilution
methods, while for several automated commercial systems
correlation to reference methods was unacceptably low [30].
More recently, the validity of antimicrobial susceptibility
testing by any method has been scrutinized. A laboratory study to
evaluate the effect of phenotypic variability on the reproducibility
of susceptibility testing found a mean of four morphotypes per
sputum and four antibiograms per morphotype. In addition, there
was a poor correlation of the results both within and between
laboratories. Susceptibility of pooled cultures did not correlate
with the results for individual organisms, with the pooled cultures
missing resistant organisms [31]. Very few studies have been
done to evaluate the importance of susceptibility testing in CF.
However, clinical trials using inhaled antimicrobials have not
seen any correlation of clinical response with susceptibility
breakpoints [17,18] and minimal clinical impact was demon-
strated when routine susceptibility testing of P. aeruginosa in
chronic CF infections was decreased by 56% at an adult CF clinic
in the UK [32].
These data bring into question the relevance for CF of
the susceptibility testing recommendations and guidelines of
the European Committee on Clinical Laboratory Standards
(ECCLS), the Clinical Laboratory Standards Institute (CLSI)
and other regulatory bodies in microbiology. Standard testing
methods and breakpoints were developed specifically for acute
bloodborne and urinary tract infections caused by a single
organism. This is in distinct contrast with the situation in CF
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lung and airways, and frequently polymicrobial; among CF
isolates there is also marked phenotypic variability within
species. Thus novel, CF-specific methods of susceptibility testing
may be more clinically relevant.
4.2. Novel methods of susceptibility testing in CF
Several novel methods of susceptibility testing have been
developed for CF isolates, but none so far has demonstrated a
clear-cut correlation with clinical outcomes. These methodsDilution and culture 
on selective media
48 hrs 
CF respiratory sample
Subculture
24 hrs 
Final identific
(confirm by 16S r
Antibiotic
susceptibility
testing
Susceptibility 
results
20-24 hrs
I
Phenotypic 
characterization
rtPBiochemical 
Testing
Pure colonies
Simultaneous
24 hrs
1
2
3
4
5 6
24 hrs
A
Dilution and culture
on selective media
48 hrs
CF respiratory sample
Subculture
24 hrs
Final identification
(confirm by 16S rRNA seque
Antibiotic
susceptibility
testing
Susceptibility 
results
20-24 hrs
If no t
16S r
seque
MALDI-TOFd
< 10 min
Pure colonies
Simultaneous
1
2
3 4
48 hrs
B
48have attempted to look at conditions more relevant to CF
respiratory tract infections including antimicrobial combination
testing, biofilm testing, and testing under anaerobic and
microaerophilic conditions.
Drug combination testing has included both synergy testing
and multiple combination bactericidal testing. A Cochrane
review by Waters and Ratjen [33] evaluated available data on
combination antimicrobial susceptibility testing in CF and
determined that there is insufficient evidence to determine the
effect of choosing antimicrobials based on combination
testing.48 hrs
ation
RNA sequencing if other methods discordant)
<10 min
f no typical CF pathogens: report as negative
CR MALDI-TOF
4-6 hrs
7
ncing if other methods discordant)
ypical CF pathogens and patient symptomatic:
RNA sequencing, rtPCRor next generation  
ncing directly on sample 
 hrs
7J.L. Burns, J.-M. Rolain / Journal of Cystic Fibrosis 13 (2014) 1–9Standard antimicrobial susceptibility testing is performed
on planktonic bacterial cultures while organisms in the CF
airways grow as biofilms. Thus, a number of investigators have
examined the role of antibiotic susceptibility testing of biofilm-
grown P. aeruginosa in directing treatment of CF patients.
Moskowitz et al. [34] performed a prospective randomized trial of
stable CF patients, comparing therapy directed by standard
susceptibility testing with therapy directed by biofilm testing.
Both patient groups improved and no significant difference was
seen in microbiological or clinical analyses.
Other conditions that may be more relevant than the use of
current ECCLS or CLSI standards for antimicrobial activity in CF
airway infections include the use of an artificial sputum medium,
growth under microaerophilic conditions, and prolonged incuba-
tion. Another approach with potential for revolutionizing suscep-
tibility testing in CF isolates is analysis of antimicrobial resistance
genes by metagenomics or whole genome sequencing. This was
recently demonstrated in a series of 200 isolates with high
concordance between phenotypic and predicted antimicrobial
susceptibility based on gene sequence [35].
5. Next generation sequencing methods
Next generation sequencing is the term applied to sequenc-
ing strategies such as pyrosequencing and dye termination and
ligation methods that enable sequencing of long stretches of
DNA and analysis of whole genomes. These methods have
revolutionized sequencing by increasing throughput, afford-
ability and simplicity. There have been many recent develop-
ments that have decreased the cost and increased the efficiency
of DNA sequencing and these hold the potential for routine
diagnostic use in the near future.
While PCR and DNA sequencing of individual genes are used
as adjunct methods for organism identification and demonstration
of antimicrobial resistance in most diagnostic laboratories, the
use of next generation high-throughput sequencing methods
directly on patient samples is primarily a research tool at this
time. However, as sequencing costs decrease and the technology
becomes increasingly available in laboratories, the opportunity
presents itself to provide real-time culture-independent results to
clinicians [36].Fig. 1. Comparison of current and proposed methods for CF respiratory sample proces
medium (48 h for the majority of organisms to be detectable). Step 2: Subculture to recov
characterization may include examination for beta hemolysis, colonymorphology includ
is done by examination of a purified colony and does not require additional inc
(minutes). Step 5: Biochemical testing for non-lactose fermenting gram negative
oxidation–fermentation reactions with various sugars including glucose, maltose, su
to final identification or further testing (24 h). Step 6: Real-time polymerase chain r
pure colonies or may be delayed until after biochemical testing (4–6 h). Step 7: MA
straightforward sample with an easy to identify P. aeruginosawould take a minimum
with multiple atypical organisms could take as long as 102 h to final identification
selective agar are still required (48 h). Step 2: Subculture to recover pure colonie
identification may be performed on isolates from the primary culture plate when iso
identification is important for patient management (Steps 1 and 4 in the proposed sc
this situation, a final result would be available within 48 h. However, pure colonies
final results would be available at 72 h. The technologist time and supply costs are m
methods.The areas in which next generation sequencing seems poised to
contribute the most to clinical care at this time include rapid
detection of multiple antibiotic resistance determinants, improved
taxonomic identification and real time outbreak investigation. The
utility of sequencing methods to detect antibiotic resistance has
been demonstrated by Zankari [35] and offers the advantage of
being able to test for hundreds of beta-lactamases and aminogly-
coside modifying enzymes. With the marked phenotypic variabil-
ity of CF clinical isolates from chronic infections, the use of whole
genome sequencing for taxonomic identification of all of the
organisms in a sputum sample offers potential to rapidly detect
both traditional pathogens and also anaerobic and fastidious
organisms that might otherwise be missed using current culture
methods. Although molecular epidemiology is not traditionally
the purview of clinical diagnostic microbiology laboratories, once
the equipment is available and protocols are in place whole
genome sequencing performed as a part of resistance investigation
and organism detection may lead to earlier discovery of highly
transmissible organisms.
The routine use of next generation sequencing methods in
clinical microbiology laboratories for direct detection of organ-
isms in CF patient samples is currently limited by lack of
equipment and expertise. In addition with our limited under-
standing of the clinical importance of many organisms that we
can currently detect in the CFmicrobiome, the analysis of the data
generated by whole genome sequencing remains prohibitive in
many clinical microbiology laboratories. Analysis of sequencing
data from highly diverse polymicrobial samples requires the
organization and interpretation of large amounts of data and not
all clinical diagnostic laboratories are staffed with technologists
with the expertise needed.
Like all methods, next generation sequencing can have
drawbacks. For example, sequence data is only as reliable as the
sequence databases that are available. And although the price of
sequencing is markedly decreased from a decade ago, equipment
and reagents are generally much more expensive than culture-
based microbiology. Most important, diagnostic laboratories
processing patient samples are highly regulated and the clinical
validation and approval of molecular assays are required. As
technology changes rapidly, regulatory bodies such as CLSI and
ECCLS will need to be very responsive to these changes. Despitesing for bacteria. A: Current procedures. Step 1: Dilution and culture on selective
er pure colonies (24 h). Step 3: Susceptibility testing (20–24 h). Step 4: Phenotypic
ing pigmentation, mucoid phenotype, and metallic sheen, and oxidase activity. This
ubation. This can lead to immediate final identification based on phenotype
bacilli may include: arginine dihydrolase, lysine decarboxylase, and urease,
crose, mannitol and xylose, and growth at 42 °C. Biochemical testing may lead
eaction (rtPCR) using single or multiple targets may be done immediately from
LDI-TOF MS identification (less than 10 min). In the current schema, the most
of 72 h from start to finish (Steps 1, 2, 3 and 4). The most complicated sample
(Steps 1, 2, 3, 4, 5 and 6). B: Proposed method. Step 1: Dilution and culture on
s (24 h). Step 3: Susceptibility testing (20–24 h). Step 4: MALDI-TOF MS
lated and easily visible individual colonies are present, especially if immediate
hema; Step 3, susceptibility testing, would require an additional 20 to 24 h). In
from subculture are more frequently used (Steps 1, 2, 3 and 4). In this scenario,
uch lower with MALDI-TOF identification compared with other identification
8 J.L. Burns, J.-M. Rolain / Journal of Cystic Fibrosis 13 (2014) 1–9these current limitations, for culture negative samples, direct
sequencing strategies hold great potential as adjunctive methods.
6. Combined molecular and culture-based methods for the
clinical evaluation of CF respiratory samples
6.1. Comparison of culture-based microbiology and molecular
analysis in CF
The advent of non-culture methods for CF microbiology has
transformed our understanding of the microbial ecology of CF
airway infections [4,5,8,37]. The airway microbiome has been
found to be much more diverse than previously thought based
on bacterial culture, and a relationship between that diversity
and pulmonary function has been identified [38]. Data from
these and other molecular analyses have added several layers of
complexity to our understanding of an already multifaceted
system. While it is too early for this knowledge to have broadly
impacted clinical management, this data is invaluable to our
long term progress.
It is clear that both culture-based and culture-independent
microbiology methods can contribute to the clinical management
of CF airway infections and, in many ways, the two methods are
complementary. Benefits of culture-based microbiology include
the relatively inexpensive cost and standardized methods that
allow portability from lab to lab, the ability to identify only viable
organisms, and the easy phenotypic characterization of organisms
(e.g. antibiotic susceptibility, mucoidy, small colony variants).
The addition of MALDI-TOF MS has improved the accuracy of
identification and shortened the time to final results. Cultures also
yield individual organisms that can be archived for further study
including epidemiological investigations when outbreaks occur,
the testing of new antimicrobials, and research examining the
progression of airway disease. On the other hand, culture-
independent methods allow precise identification based on
sequencing or RFLP patterns, detection of organisms present in
low numbers, and characterization of the entire community of
organisms present. Quantitative real-time PCR performed directly
on CF oropharyngeal and sputum samples appears to offer
advantages for detection of both H. influenzae and anaerobes
[39]. Molecular methods also have the potential to yield results
much more rapidly than culture. Both strategies may be
performed quantitatively and both appear to have the ability to
identify the majority of known pathogens present [9,37]. As
clinicians and microbiologists we need to determine how best to
use these tools to manage CF patients.
In CF, current practice of diagnostic microbiology uses
primarily culture-based methods while recent ecological research
describing the microbiota and its diversity relies primarily on
non-culture methods. We propose a model for clinical CF
microbiology that combines culture-based and molecular meth-
ods. In Fig. 1 we compare the current strategies with our proposed
model, which has comparable accuracy and improved efficiency.
Many clinical laboratories already use both culture based and
non-culture based methods to some extent with their utilization of
real-time PCR, sequencing and MALDI-TOF MS for identifica-
tion of organisms recovered from culture. Each has advantages,but we endorse the use of MALDI-TOF MS for routine
identification of organisms isolated from CF respiratory samples,
because it is very rapid and is accurate for a large number of
organisms. Some isolates including Burkholderia spp. and
non-aeruginosa pseudomonads may require additional workup
using real-time PCR or sequencing for identification to the
species level. Although at this time routine direct identification of
the organisms present in a CF sample prior to culture using
terminal restriction fragment length polymorphism, PCR or next
generation sequencing is not practical in the majority of clinical
diagnostic laboratories, it may be very beneficial to reexamine
samples that do not yield traditional CF pathogens on culture in
reference laboratories that perform more complex molecular
techniques.
Antibiotic susceptibility testing using traditional culture-based
techniques and approved methods for CF isolates [30] is still
recommended, although defining the relevance of these standard
test methods to CF will be important. Possible changes in the
future include performance of conventional antimicrobial sus-
ceptibility testing at less frequent intervals, revision of suscep-
tibility breakpoints for CF isolates, the use of more CF-relevant
media and growth conditions, and the application of molecular
methods for detection of resistance.7. Conclusions
Clinical microbiology is changing rapidly and ongoing
research into the CF airway microbiome is adding both to our
knowledge and to our uncertainty about which organisms
should be evaluated. Clinicians and microbiologists need to be
open to trying new methods and strategies to help us better
understand the complexity of airway infections in CF and their
impact on patient clinical status.References
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